WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe ...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe ...
Abata Therapeutics has launched with $95 million in series A funding to take cell therapy into a new realm: the treatment of multiple sclerosis. The investment comes primarily from Third Rock Ventures ...
CEO Samantha Singer said Abata Therapeutics Inc. “spent a considerable amount of time finding the right indication” for its approach, which deploys autologous regulatory T cells (Tregs) made to ...
Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's ...
The Series A financing announced Wednesday was led by Third Rock Ventures. Boston-based Abata is developing therapies from regulatory T cells (Tregs), the counterpart to T cells. While T cells attack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results